MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics (NASDAQ: INKT) announced two SITC 2026 poster presentations on preclinical findings in treatment-resistant colorectal cancer and senescent cells.
agenT-797 enabled tumor-cell killing in a human organoid model, a laboratory-grown tissue model, of checkpoint inhibitor–resistant colorectal cancer liver metastases. The research examines agenT-797 alone and with botensilimab and balstilimab, and supports the rationale for an ongoing Phase 2 combination trial at Scripps.
Native agenT-797 and engineered MiNK-215 eliminated senescent tumor cells and fibroblasts in laboratory models. The senescent-cell poster is scheduled for November 6, 2026, and the colorectal cancer poster for November 7, 2026, at the Phoenix Convention Center.
MiNK Therapeutics (INKT) has been selected to provide its agenT-797 cell platform for an ARPA-H-funded team developing room-temperature cell therapy storage technologies.
MiNK joins the Reversible Ambient Biostabilization team led by The Charles Stark Draper Laboratory within ARPA-H’s four-year BioStabilization Systems program. ARPA-H has committed up to $87 million across the program, which aims to move living medicines from cryogenic storage near -196°C toward storage near 21°C. This is program-wide funding, not a disclosed award to MiNK. MiNK will contribute its clinical-stage immune-cell platform, manufacturing infrastructure and development expertise. The team plans to use AI-assisted experiments and freeze-assisted droplet drying to develop and evaluate stabilization technologies.
MiNK Therapeutics (NASDAQ: INKT) reported second quarter 2026 results and clinical progress for its iNKT cell therapy agenT-797. The company initiated randomized Phase 2 trial C-1300-02 in acute lung injury/ARDS in Lviv, Ukraine, under a U.S. IND, evaluating agenT-797 plus standard of care versus placebo.
Initial Day 28 observations from the first treated ventilated patients showed they were alive and afebrile, with improved oxygenation, ARDS resolution, return to spontaneous breathing, liberation from vasopressor support, infection control, and reduced inflammatory markers; no major serious adverse events were attributed to agenT-797. MiNK also launched a paid named-patient access program in Brazil with Orphan Drug Consulting, providing per-patient, non-promotional revenue and cross-border infrastructure. Cash was $8.8 million at June 30, 2026, and Q2 net loss narrowed to $3.1 million versus $4.2 million a year earlier.
MiNK Therapeutics (NASDAQ: INKT) reported early observations from an ongoing randomized Phase 2 trial of its off-the-shelf iNKT-cell therapy agenT-797 in patients with severe hypoxemic pneumonia, presented at the 2026 Military Health System Research Symposium.
According to the company, the first treated patients were alive and afebrile at Day 28, with substantially improved hemodynamics, mental status, oxygenation, and removal from ventilator and vasopressor support. Microbiological data indicated control of baseline infections, while blood and bronchoalveolar lavage analyses showed reduced inflammatory markers and biological changes associated with immune recovery, epithelial repair, and pulmonary vascular recovery. No major serious adverse events were attributed to agenT-797 in these initial patients. Enrollment in study C-1300-02 continues in Lviv, Ukraine, with U.S. sites opening and additional data expected in early 2027.
MiNK Therapeutics (NASDAQ: INKT) will report its financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026. The company will also provide a corporate update focused on the clinical advancement of agenT-797, its off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy, in acute lung injury.
Management will host a conference call and webcast at 8:30 AM ET on August 13, 2026 to review the financials, share new clinical data on agenT-797 in patients with pulmonary injury, and discuss the launch of MiNK’s named-patient program. Dial-in options include a New York line at (646) 307-1963, a USA & Canada toll-free line at (800) 715-9871, using Conference ID 8767945. A live webcast and replay will be available on the Events & Presentations page of MiNK’s investor relations website.
Agenus (Nasdaq: AGEN) reported second quarter 2026 revenue of $34.5 million, up from $25.7 million a year earlier, including $6.4 million in pre-commercial BOT+BAL revenue and $28.1 million in non-cash royalty revenue. Operating income was $11.3 million versus a $16.7 million loss, and net loss was $0.6 million. Cash was $18.7 million at quarter-end, excluding an oversubscribed July private placement that raised $85 million upfront with up to $255 million in potential warrant proceeds.
The financing is expected to fund ROBBIN, a planned global Phase 3 trial of neoadjuvant BOT+BAL in about 850 high-risk Stage II/III MSS colon cancer patients, targeting an annual U.S. market of roughly 38,000 patients. ROBBIN initiation and first dosing are anticipated in Q1 2027. Agenus highlighted NEST/UNICORN neoadjuvant data showing ~30% pCR and ~40% MPR among 38 patients, and metastatic data with median overall survival of 21.2 months in refractory MSS colorectal cancer. The company grew BOT+BAL access-program revenue and, to prioritize ROBBIN, stopped future funding for the CCTG-sponsored BATTMAN Phase 3 trial, which CCTG then terminated.
MiNK Therapeutics (NASDAQ: INKT) announced its 2026 Annual Shareholders Meeting will be held virtually on June 17, 2026. The meeting starts at 9:30 a.m. ET, with registration beginning at 9:15 a.m. ET. A live webcast and replay will be available online.
MiNK Therapeutics (NASDAQ: INKT) has dosed the first patient in its randomized Phase 2 trial of agenT-797 plus standard of care vs placebo in severe acute lung injury meeting Global ARDS criteria. The study, authorized in Ukraine and under an active U.S. IND, will assess ICU outcomes such as survival, ventilator-free days, ICU recovery, pathogen control, and immune function, with preliminary data expected in the second half of 2026.
Agenus (Nasdaq: AGEN) reported retrospective ASCO 2026 data using Noetik’s AI TARIO-2 platform to analyze routine pretreatment H&E tumor images from 113 patients treated with botensilimab (BOT) plus balstilimab (BAL).
In refractory MSS metastatic colorectal cancer without active liver metastases, an AI-identified subgroup showed a 64% response rate to BOT+BAL versus 9% in the remaining cohort, and significantly better overall survival, with median OS not reached and a hazard ratio of 0.18. TARIO-2 outperformed benchmark pathology foundation models and may support future image-based biomarker strategies for BOT+BAL, subject to prospective validation.
Agenus (Nasdaq: AGEN) reported Phase 2 data for botensilimab (BOT) plus balstilimab (BAL) in advanced checkpoint-refractory cutaneous melanoma (36 patients) to be presented at ASCO 2026.
Median overall survival was 16.6 months, 2‑year survival 42%, and median duration of response was not reached, with 86% of responders in response at 12 months.